Avalyn Pharma Inc. AVLN
31.17 USD +1.67 (+5.66%)
At closeNov 10, 2026, 4:01 PM EST
31.17 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
28.71 Day range 31.51
22.24 52-week range 40.17
- YTD
- +5.70%
- 1 year
- +5.70%
News
globenewswire.com Avalyn to Present at Upcoming Investor Conferences BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious,…
benzinga.com This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.
benzinga.com Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60 Raymond James analyst Tiago Fauth initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Outperform rating and announces Price Target of $60.
benzinga.com Avalyn Pharma Says Respiratory Research Publishes Detailed Results From Two Phase 1 Clinical Trials Of AP02 In Healthy Volunteers And Patients With IPF, Validating Inhaled Antifibrotic Approach Results validate Avalyn’s approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving…- benzinga.com Avalyn Pharma Reports New Data Showing Predicted Aerosol Distribution Of AP01 And Survey Data Highlighting Patient Perspectives On Participation In Clinical Studies For Idiopathic Pulmonary Fibrosis In silico modeling predicts robust AP01 distribution in healthy and fibrotic lungs, even in severe diseasePatient survey findings suggest that clear communication, transparent discussions of…
benzinga.com Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57 Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and raises the price target from $53 to $57.
benzinga.com Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate Avalyn Pharma (NASDAQ:AVLN) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.53) by 22.64 percent.
benzinga.com Evercore ISI Group Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $51 Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Outperform rating and announces Price Target of $51.
benzinga.com This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on AVLN stock.
benzinga.com Guggenheim Initiates Coverage On Avalyn Pharma with Buy Rating, Announces Price Target of $80 Guggenheim analyst Seamus Fernandez initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Buy rating and announces Price Target of $80.- benzinga.com Morgan Stanley Initiates Coverage On Avalyn Pharma with Overweight Rating, Announces Price Target of $53 Morgan Stanley analyst Judah Frommer initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Overweight rating and announces Price Target of $53.
- benzinga.com Avalyn Pharma To Present Updated Findings From ATLAS Open-Label Extension Trial Highlighting Long-Term Tolerability Profile Of AP01 For Treatment Of Pulmonary Fibrosis, At EULAR 2026 Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced an…
- benzinga.com Avalyn To Present Findings From Usability Study For eFlow Nebulizer System At American Thoracic Society 2026 International Conference May 15-20 The company's poster presentations are listed below and will be presented in the following session: Thematic Poster Session B39 – Breath and Burden: Diffuse Lung Diseases and Daily Life, Monday, May…